Zoeller, J. J., Vagodny, A., Daniels, V. W., Taneja, K., Tan, B. Y., DeRose, Y. S., . . . Brugge, J. S. (2020). Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res.
Citação norma ChicagoZoeller, Jason J., et al. "Navitoclax Enhances the Effectiveness of EGFR-targeted Antibody-drug Conjugates in PDX Models of EGFR-expressing Triple-negative Breast Cancer." Breast Cancer Res 2020.
Citação norma MLAZoeller, Jason J., et al. "Navitoclax Enhances the Effectiveness of EGFR-targeted Antibody-drug Conjugates in PDX Models of EGFR-expressing Triple-negative Breast Cancer." Breast Cancer Res 2020.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.